(Q39792508)

14 September 2017

title

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. (English)

1 reference

14 September 2017

4

1 reference

14 September 2017

A A Mian

1

1 reference

14 September 2017

C Oancea

series ordinal

2

1 reference

14 September 2017

Z Zhao

series ordinal

3

1 reference

14 September 2017

M Ruthardt

series ordinal

5

1 reference

14 September 2017

publication date

1 October 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

23

1 reference

14 September 2017

issue

12

1 reference

14 September 2017

page(s)

2242-2247

1 reference

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Resistance to imatinib: mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Therapy options in imatinib failures

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Autoinhibition of Bcr-Abl through its SH3 domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Regulation of the c-Abl and Bcr-Abl tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.194

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.194

1 reference

release_vcaxc3guyngrngsedmyrcafizi

14 September 2017

Fatcat ID

0 references

1 reference